Doxycycline in the Coronavirus Disease 2019 Therapy

Karolina Dorobisz,1 Tadeusz Dorobisz,2 Dariusz Janczak,2 Tomasz Zato&nacute;ski1 1Department of Otolaryngology, Head and Neck Surgery, Wroclaw Medical University, Wroclaw, Poland; 2Department of Vascular Surgery, Wroclaw Medical University, Wroclaw, PolandCorrespondence: Karolina Dorobisz Email...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dorobisz K, Dorobisz T, Janczak D, Zatoński T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	covid-19 covid-19 therapy doxycycline sars-cov-2 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/67750291f4de4589a94402750e56b5e8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:67750291f4de4589a94402750e56b5e8
record_format	dspace
spelling	oai:doaj.org-article:67750291f4de4589a94402750e56b5e82021-12-02T17:25:47ZDoxycycline in the Coronavirus Disease 2019 Therapy1178-203Xhttps://doaj.org/article/67750291f4de4589a94402750e56b5e82021-09-01T00:00:00Zhttps://www.dovepress.com/doxycycline-in-the-coronavirus-disease-2019-therapy-peer-reviewed-fulltext-article-TCRMhttps://doaj.org/toc/1178-203XKarolina Dorobisz,1 Tadeusz Dorobisz,2 Dariusz Janczak,2 Tomasz Zato&nacute;ski1 1Department of Otolaryngology, Head and Neck Surgery, Wroclaw Medical University, Wroclaw, Poland; 2Department of Vascular Surgery, Wroclaw Medical University, Wroclaw, PolandCorrespondence: Karolina Dorobisz Email dorobiszkarolina@gmail.comAbstract: Acute respiratory syndrome, associated with coronavirus 2 (SARS-CoV-2), is the most important medical and epidemic problem of today. The biggest challenge is to find an effective treatment and to reduce the need for hospitalisation. In the article, the patients with mild to moderate coronavirus disease 2019 (COVID-19) treated with doxycycline with significant improvement have been discussed. Doxycycline is a known antibiotic, but also an anti-inflammatory and immunomodulatory drug, so it seems to be ideal for the treatment of COVID-19. Doxycycline, as an easily available and low-cost medication, should be considered as a COVID-19 therapy in all patients in the first days of the symptoms of a SARS-CoV-2 infection. Due to its immunomodulatory, anti-inflammatory, cardioprotective and antiviral effects, it seems to be an ideal drug for patients with mild, moderate and severe disease. A large multicentre study is needed to evaluate the effects of this medication.Keywords: COVID-19, COVID-19 therapy, doxycycline, SARS-CoV-2Dorobisz KDorobisz TJanczak DZatoński TDove Medical Pressarticlecovid-19covid-19 therapydoxycyclinesars-cov-2Therapeutics. PharmacologyRM1-950ENTherapeutics and Clinical Risk Management, Vol Volume 17, Pp 1023-1026 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	covid-19 covid-19 therapy doxycycline sars-cov-2 Therapeutics. Pharmacology RM1-950
spellingShingle	covid-19 covid-19 therapy doxycycline sars-cov-2 Therapeutics. Pharmacology RM1-950 Dorobisz K Dorobisz T Janczak D Zatoński T Doxycycline in the Coronavirus Disease 2019 Therapy
description	Karolina Dorobisz,1 Tadeusz Dorobisz,2 Dariusz Janczak,2 Tomasz Zato&nacute;ski1 1Department of Otolaryngology, Head and Neck Surgery, Wroclaw Medical University, Wroclaw, Poland; 2Department of Vascular Surgery, Wroclaw Medical University, Wroclaw, PolandCorrespondence: Karolina Dorobisz Email dorobiszkarolina@gmail.comAbstract: Acute respiratory syndrome, associated with coronavirus 2 (SARS-CoV-2), is the most important medical and epidemic problem of today. The biggest challenge is to find an effective treatment and to reduce the need for hospitalisation. In the article, the patients with mild to moderate coronavirus disease 2019 (COVID-19) treated with doxycycline with significant improvement have been discussed. Doxycycline is a known antibiotic, but also an anti-inflammatory and immunomodulatory drug, so it seems to be ideal for the treatment of COVID-19. Doxycycline, as an easily available and low-cost medication, should be considered as a COVID-19 therapy in all patients in the first days of the symptoms of a SARS-CoV-2 infection. Due to its immunomodulatory, anti-inflammatory, cardioprotective and antiviral effects, it seems to be an ideal drug for patients with mild, moderate and severe disease. A large multicentre study is needed to evaluate the effects of this medication.Keywords: COVID-19, COVID-19 therapy, doxycycline, SARS-CoV-2
format	article
author	Dorobisz K Dorobisz T Janczak D Zatoński T
author_facet	Dorobisz K Dorobisz T Janczak D Zatoński T
author_sort	Dorobisz K
title	Doxycycline in the Coronavirus Disease 2019 Therapy
title_short	Doxycycline in the Coronavirus Disease 2019 Therapy
title_full	Doxycycline in the Coronavirus Disease 2019 Therapy
title_fullStr	Doxycycline in the Coronavirus Disease 2019 Therapy
title_full_unstemmed	Doxycycline in the Coronavirus Disease 2019 Therapy
title_sort	doxycycline in the coronavirus disease 2019 therapy
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/67750291f4de4589a94402750e56b5e8
work_keys_str_mv	AT dorobiszk doxycyclineinthecoronavirusdisease2019therapy AT dorobiszt doxycyclineinthecoronavirusdisease2019therapy AT janczakd doxycyclineinthecoronavirusdisease2019therapy AT zatonskit doxycyclineinthecoronavirusdisease2019therapy
_version_	1718380913583194112

Doxycycline in the Coronavirus Disease 2019 Therapy

Ejemplares similares